First successful clinical trial of VU319 brings Alzheimer’s treatment one step closer

Written By Hannah Schaeffer

Researchers at the Warren Center for Neuroscience Drug Discovery, a clinical stage biotech within the Vanderbilt University School of Medicine Basic Sciences, have detailed the successful drug discovery of a Phase I Single Ascending Dose clinical trial of VU319, a drug for memory loss in people with Alzheimer’s disease and schizophrenia.

Read more here.

Hannah Schaeffer
Previous

Tennessee Bureau of Investigation and Vanderbilt researchers to collaborate on opioid crisis, cannabis education
Next

Unlocking the mind: Vanderbilt Warren Center pioneers breakthroughs in neuroscience drug discovery